Lokavant in the News

Spectrum v15 reduces 5 weeks of manual work to 5 minutes, provides study sponsors and CROs a fast way to navigate the path to successful enrollment

New solution supports trial feasibility prediction, optimization, and control throughout the trial

New advisory board and executive hire bring domain-rich experience to Lokavant

New clinical trial data hub aggregates, centralizes and standardizes data across sources Lokavant, the clinical trial intelligence platform company, announces PRIZM™ Clinical Data Hub (CDH),...

Lokavant, the clinical trial intelligence platform company, today announces an $8 million strategic investment from global business titan Mitsui & Co. Ltd. to expand its AI-optimized platform across...

As increased diversity of patient populations who participate in clinical trials becomes more entrenched as a modern business, clinical, and regulatory requirement, new trial technologies and tools...

Emerging technologies are making waves in biopharma research. A recent article in Citeline In Vivo discusses how machine learning (ML) is being used to improve clinical trial diversity. By analyzing...

Rohit Nambisam is CEO of Lokavant, OSP caught up with him at DIA Global in Boston earlier this summer to find out more about him and the work he is passionate about.

New analytics technology reduces trial costs and timelines; initial case shows it can cut the number of sites needed for a trial by 36% Lokavant, the clinical trial intelligence platform company,...

Attempts at improving diversity, equity, and inclusion (DEI) access across U.S. healthcare is a much-welcomed, if not long-overdue, development in recent years. SubstantiveDEI legislation was signed...

Lokavant CEO Rohit Nambisan recently joined Jared Taylor, host of BioBreakthrough, for an enlightening conversation about the unique challenges and exciting opportunities in the field of clinical...

Clinical trial participation amongst minority groups in the U.S. is woefully inadequate a challenge that has plagued this industry for years. In December 2022, substantive diversity, equity, and...

Attempts at improving diversity, equity, and inclusion (DEI) access across US healthcare is a much-welcomed, if not long-overdue, development in recent years. Substantive DEI legislation was signed...

In the latest episode of Brad Hightower's Note to File Podcast, Lokavant CEO Rohit Nambisan engaged in an enlightening conversation about the evolution of clinical trials. The discussion was...

The year 2020 was a watershed moment for many reasons, but notably, it cast a light on the pervasive health and social inequities that have long marred the U.S. The COVID-19 pandemic hit diverse...

A data-agnostic integration platform for optimizing trial planning and conduct hit the streets three years ago, bringing near-real-time insights about every participant, site, country, region, and...

NEW YORK – April 26, 2023 – Lokavant, the clinical trial intelligence platform company, today announced its Product Advisory Board. This esteemed group of industry leaders will help drive the...

RecentlyRohit Nambisanthe CEO of New York City-based Lokavant connected with TrialSite’s founder Daniel O’Connor for a review of the startup’s origins, emerging value proposition and directions....

Lokavant is a company looking to fix the fragmentation problem in clinical trials, which has been caused by the number of trials nearly quadrupling since 2010, leading to far more data being...